Medical Oncologist
CION Cancer Clinics
Sorafenib or lenvatinib: how the choice is made today | CION Cancer Clinics
Sorafenib and lenvatinib work in a similar way, and lenvatinib was found to work at least as well as sorafenib as a first treatment. The choice now turns on how much of the liver is involved, which side effects you can manage and your other illnesses. This page explains where these tablets fit today, what tips the choice, and who they do not suit. At CION Cancer Clinics, a multidisciplinary tumour board weighs your liver function and your scans before recommending any treatment.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed October 2026, next review due October 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
The short answer
Should I take sorafenib or lenvatinib first?
Sorafenib and lenvatinib work in a similar way, and a large trial found lenvatinib works at least as well as sorafenib as a first treatment. The choice between them now turns mostly on the extent of the cancer, on which side effects you can live with, and on your other illnesses.
Where these tablets fit today
For most people with advanced hepatocellular carcinoma (HCC, cancer that starts in the liver) and a liver that still works well, an immunotherapy combination is now the usual first treatment. Tablets come first when immunotherapy is not safe or not possible, and they are often used next when immunotherapy stops working. Our page on choosing between immunotherapy and tablets covers that earlier decision.
Who this page is not about
This page is about cancer that started in the liver. If your scan shows cancer that spread to the liver from the bowel, breast or elsewhere, these tablets are rarely used. Start with what secondary liver cancer means instead.
Neither tablet is a weaker choice. Each suits a slightly different person.What tips the choice
What makes my doctor lean one way or the other?
No blood test picks the tablet. The decision rests on four practical questions.
How much of the liver is involved
The main lenvatinib trial left out people whose cancer filled about half the liver or more, or had grown into the main portal vein (the big vein carrying blood into the liver). In those situations many oncologists prefer sorafenib, because it was studied there.
Your blood pressure and kidneys
Lenvatinib often raises blood pressure and can leak protein into the urine. If your blood pressure is already hard to control, or your kidneys are weak, sorafenib may be easier.
Your hands, feet and gut
Sorafenib more often causes sore, thickened skin on the palms and soles, and diarrhoea. For a farmer, a driver or anyone on their feet all day, that matters.
What came before
If you have already had immunotherapy, your liver function, weight and fitness at that point shape which tablet is safer to try next.
- Previous transplant
- Heart disease
- Recent bleeding
Not sure whether this applies to you?
Ask an oncologistSide by side
How do sorafenib and lenvatinib compare in practice?
Sorafenib
Lenvatinib
The older tablet, with the longest experience in liver cancer
Newer, and found at least as effective as a first treatment
Studied in people with portal vein involvement
Not studied in heavy liver involvement or main portal vein spread
Common problems: sore hands and feet, diarrhoea, tiredness
Common problems: high blood pressure, tiredness, poor appetite, weight loss
More often shrinks the cancer only a little
More often shrinks the cancer visibly on a scan
Generic versions sold in India
Generic versions sold in India
Step by step
What happens once a tablet is chosen?
Baseline checks
Blood tests for liver and kidney function, a urine test, your blood pressure and weight are recorded. These give the team a starting point to compare against. If you carry hepatitis B, your antiviral tablets are checked with a hepatologist before the first dose.
A starting plan
Your oncologist sets the starting strength based on your weight, liver function and fitness. Many people later need a lower strength, and that is normal, not a failure.
Close watching early on
Most side effects appear in the first few weeks of treatment. You will be told who to call and which problems need a same-day call. Keep a simple diary of blood pressure, stools and skin changes to bring to each visit, because small problems are easier to fix early.
A review scan
A scan after a few months shows whether the cancer is shrinking, stable or growing. Stable is a good result with these tablets. Read how response is assessed.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Not for everyone
Who do these tablets not suit?
Neither tablet usually suits someone whose liver is failing badly, with Child-Pugh C function. At that point the tablets tend to cause harm without giving useful time, and care rightly focuses on comfort and the liver itself.
When lenvatinib is the harder choice
Lenvatinib is usually avoided or used with great care in people with blood pressure that will not settle, heavy protein in the urine, a recent heart attack or stroke, or a recent serious bleed. It was also not tested in people whose cancer had spread into the main portal vein.
When sorafenib is the harder choice
Sorafenib can be hard on people with existing skin disease on the feet, diabetes affecting the feet, or bowel problems that already cause loose stools. It also needs care in people with heart rhythm problems.
Liver function in between
For people with Child-Pugh B liver function, the evidence for both tablets is thin. Some are offered a cautious trial at a lower strength; others are better served by supportive care alone. See systemic treatment with Child-Pugh B.
Being straight with you
What this page cannot tell you
It cannot tell you which tablet is right for you, or how long it will keep the cancer under control. Trials compare large groups, and averages say little about one person. Your oncologist can weigh your scans, blood results and daily life together.
It does not cover how to take them
Timing, food, missed tablets and side-effect care belong on our medicine pages. For the detailed comparison of the two drugs, read lenvatinib versus sorafenib. Never change the strength or stop a tablet without talking to your team.
Prices change
Generic versions have made both tablets more affordable in India, but prices, brands and scheme cover change often. Ask for a written, itemised estimate before you start, and ask whether a generic version is suitable for you.
If you were given one tablet and wonder why not the other, ask. A clear answer is your right, and a second opinion is always reasonable.Questions we are asked
Common questions about sorafenib and lenvatinib
Is lenvatinib better than sorafenib?
The main trial found lenvatinib works at least as well as sorafenib, and it shrinks the cancer more often. It did not show people clearly living longer on it. For some people, especially with portal vein spread, sorafenib remains the more studied choice.
Why was I given tablets and not immunotherapy?
Usually because immunotherapy was not safe for you. Common reasons are a previous liver transplant, an autoimmune illness, untreated varices, or a recent bleed. Sometimes it is about access or cost. Ask your oncologist which reason applies to you.
Can I switch from one tablet to the other?
Switching because of side effects is sometimes done, and your team will judge whether it is sensible. If the cancer grows on one tablet, the next step is usually a different kind of treatment rather than the other tablet. That depends on what you had before.
Are generic versions as good as the brand?
Generic versions approved in India must contain the same medicine. Many families use them, and they make long treatment more affordable. Ask your oncologist which version they trust and stay with one source where you can, so any change in side effects is easier to read.
Do I still need my hepatitis B tablets?
Yes. Hepatitis B is controlled, not removed from the body, so antiviral tablets usually continue alongside cancer treatment. A hepatologist or physician decides on the antiviral. Never stop it on your own, because a flare can damage the liver.
Can these tablets be taken after a liver transplant?
Tablets can be used after a transplant with care, whereas immunotherapy is usually avoided because it can trigger rejection. Both tablets interact with some transplant medicines, so the oncologist and transplant team plan this together.
Will the cancer go away on these tablets?
The aim is control, not removal. Many people find the cancer stays the same size for a while, which is a good result. Occasionally it shrinks a lot. Nobody can promise either outcome at the start, and your scans will show how you are responding.
Where do I start if I want this decision reviewed?
Gather your scan reports, the images on a disc or link, your biopsy report if you had one, and recent blood tests. Call the CION helpline, and a medical oncologist will review them with the tumour board and explain the choice.
Your Specialists
Meet CION's liver cancer specialists. Bring your scan reports and liver blood tests.
Our medical and surgical oncologists plan liver cancer care together, weighing the tumour and how well your liver works before choosing surgery, a liver-directed procedure or medicines.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- American Cancer Society — Targeted Drug Therapy for Liver Cancer
- EASL — EASL Clinical Practice Guidelines: management of hepatocellular carcinoma
- Cancer Research UK — Treatment for liver cancer
- American Cancer Society — Treatment of Liver Cancer, by Stage
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Choosing between immunotherapy and tabletsThe decision that comes before this oneSecond-line treatment after first-line failsWhat comes next if the first tablet stops workingGeneric and biosimilar versionsHow generic tablets can lower the monthly billLenvatinib vs sorafenib for liver cancerThe drug-by-drug detail on side effects and use
Talk to us
Wondering why you were given one tablet and not the other?
Share your scans and blood reports and a medical oncologist will explain which tablet fits your liver and why. One helpline serves every CION centre.